Biotechnology company leverages AWS’s unmatched
portfolio of services to accelerate development of messenger RNA
medicines to prevent and fight diseases, including COVID-19
Today, Amazon Web Services, Inc. (AWS), an Amazon.com company
(NASDAQ: AMZN), announced that Moderna, Inc. (Nasdaq: MRNA), a
biotechnology company pioneering a new class of messenger RNA
(mRNA) medicines, has selected AWS as its preferred cloud provider,
as well as its standard for analytics and machine learning
workloads. Leveraging its mRNA platform and manufacturing facility
with the AWS-powered research engine, Moderna delivered the first
clinical batch of its vaccine candidate (mRNA-1273) against
COVID-19 to the NIH for the Phase 1 trial 42 days after the initial
sequencing of the virus. By building and scaling its operations on
the world’s leading cloud, Moderna is able to quickly design
research experiments and uncover new insights, automate its
laboratory and manufacturing processes to enhance its drug
discovery pipeline, and more easily comply with applicable laws and
regulations during production and testing of vaccine and
therapeutic candidates.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200805005965/en/
Moderna's mRNA research platform and
manufacturing facility are powered by AWS. (Image: Moderna)
Researching and developing new drugs can be complex and
expensive. Scientists have to conduct years of basic research to
understand how new diseases act at a molecular level in the human
body and need to screen thousands of different molecular compounds
(the basis for many drugs) to assess their safety and efficacy as
potential treatments. After they narrow down the pipeline,
researchers perform multiple rounds of testing in the laboratory
before advancing the most promising drug candidates for further
study. In addition, because the manufacturing requirements for
these drugs can be highly variable, pharmaceutical companies may
also need to build expensive new infrastructure or redesign
existing facilities in order to produce them. Moderna is managing
these challenges, leveraging the breadth and depth of AWS services
to simplify the research and manufacture of a new class of drugs,
based on mRNA, to treat a wide range of diseases.
Moderna has invented proprietary technologies and methods that
run on AWS to create mRNA constructs that cells recognize as if
they were produced in the body. This invention has empowered
Moderna to experiment rapidly on virtually any mRNA sequence,
easily shifting between research priorities, without investing in
new technology. Moderna runs its Drug Design Studio on AWS’s highly
scalable compute and storage infrastructure to quickly design mRNA
sequences for protein targets. It then uses analytics and machine
learning to optimize those sequences for production so that the
company’s automated manufacturing platform can successfully convert
them into physical mRNA for testing. In addition, by leveraging
Amazon Redshift – AWS’s fully managed data warehousing service –
Moderna’s scientists and engineers aggregate results from dozens of
experiments that are running in parallel and can easily query and
share insights to refine their design and production cycle
quickly.
Moderna runs all of its SAP S/4HANA workloads on AWS, including
manufacturing, accounting, and inventory management, which enables
the company to achieve greater efficiency and visibility across its
operations. AWS also powers Moderna’s highly automated production
facility, which runs AWS IoT services to connect the manufacturing
instruments, robotics, and other critical systems that quickly
deliver the mRNA constructs for experimentation. Integrating its
systems on AWS provides Moderna with the ability to trace its
manufacturing process, facilitating industry best practices in its
supply chain, manufacturing, and quality control processes. Moderna
also used AWS to essentially copy and paste its digital
manufacturing model onto its partner’s facilities for technology
transfer, giving Moderna rapid access to the additional production
capacity it needs to address global demand.
“The science behind mRNA medicines is advancing at a rapid pace,
and building Moderna’s technology platform on AWS gives our
scientists the insights, agility, and security they need to
continue to lead in the industry,” said Stéphane Bancel, Moderna’s
Chief Executive Officer. “With AWS, our researchers have the
ability to quickly design and execute research experiments and
rapidly uncover new insights to get potentially life-saving
treatments into production faster. AWS’s breadth and depth of
services are supporting our mission to create a new generation of
medicines for patients and are instrumental in our quest to develop
a vaccine for COVID-19 and other life-threatening diseases.”
“Running on AWS, Moderna has the agility to continuously refine
its research, development, and manufacturing,” said Matt Garman,
Vice President, Sales and Marketing at AWS. “Moderna is relying on
the proven performance and scale of the world’s leading cloud to
innovate and develop drug and vaccine candidates on timelines that
may have been impossible even just a few years ago.”
About Amazon Web Services
For 14 years, Amazon Web Services has been the world’s most
comprehensive and broadly adopted cloud platform. AWS offers over
175 fully featured services for compute, storage, databases,
networking, analytics, robotics, machine learning and artificial
intelligence (AI), Internet of Things (IoT), mobile, security,
hybrid, virtual and augmented reality (VR and AR), media, and
application development, deployment, and management from 77
Availability Zones (AZs) within 24 geographic regions, with
announced plans for nine more Availability Zones and three more AWS
Regions in Indonesia, Japan, and Spain. Millions of
customers—including the fastest-growing startups, largest
enterprises, and leading government agencies—trust AWS to power
their infrastructure, become more agile, and lower costs. To learn
more about AWS, visit aws.amazon.com.
About Amazon
Amazon is guided by four principles: customer obsession rather
than competitor focus, passion for invention, commitment to
operational excellence, and long-term thinking. Customer reviews,
1-Click shopping, personalized recommendations, Prime, Fulfillment
by Amazon, AWS, Kindle Direct Publishing, Kindle, Fire tablets,
Fire TV, Amazon Echo, and Alexa are some of the products and
services pioneered by Amazon. For more information, visit
www.amazon.com/about and follow @AmazonNews.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200805005965/en/
Amazon.com, Inc. Media Hotline Amazon-pr@amazon.com
www.amazon.com/pr
Amazon.com (NASDAQ:AMZN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Amazon.com (NASDAQ:AMZN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024